TY - JOUR
AU - , Van Steirteghem, A.C.
AB - Abstract A prospective randomized study was conducted to evaluate the use of adding oestradiol valerate 6 mg per os daily to intravaginal micronized progesterone (600 mg daily) as luteal supplements. The study comprised 378 infertile women superovulated with a gonadotrophin releasing-hormone agonist (GnRHa) and human menopausal gonadotrophins (HMG) for in-vitro fertilization (IVF) or zygote intra-Fallopian transfer (ZIFT). The clinical pregnancy rate was similar (29%) whether or not oestradiol valerate was added to intravaginal progesterone. Eighteen out of twenty-two endometrial biopsies were in phase, and morphological evaluations of the two luteal supplementation groups were not different. Serum hormone profiles in singleton pregnancies showed a similar day of appearance of human chorionic gonadotrophin (HCG) in both protocols but significantly lower oestradiol concentrations arose in the group without oestradiol valerate. In 32% of the singleton pregnancies, the first appearance of HCG occurred later than day 12 after HCG injection; in those ongoing pregnancies, corpus luteum rescue—as measured by significantly lower serum oestradiol and progesterone concentrations—was compromised. This study provided no evidence of any benefit of routinely supplementing GnRHa/HMG cycles with oestradiol valerate in addition to intravaginal micronized progesterone. GnRH agonists, HCG, IVF, luteal phase, oestradiol valerate This content is only available as a PDF. © Oxford University Press
TI - A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation
JO - Human Reproduction
DO - 10.1093/oxfordjournals.humrep.a137871
DA - 1993-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/a-prospective-randomized-study-on-oestradiol-valerate-supplementation-ijhfsXs6h0
SP - 40
EP - 45
VL - 8
IS - 1
DP - DeepDyve
ER -